Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Jan;120(2):139-140.
doi: 10.1038/s41416-018-0353-x. Epub 2018 Dec 11.

Desperately seeking…Models to find the right partner and the best use for checkpoint inhibitors

Francesco Bertolini  1
Affiliations
Editorial

Desperately seeking…Models to find the right partner and the best use for checkpoint inhibitors

Francesco Bertolini. Br J Cancer. 2019 Jan.

Erratum in

Abstract

Immune checkpoint inhibitors have shown unprecedented clinical activity in a variety of cancer types, but only in a fraction of patients. Promising in vivo synergies have been demonstrated between checkpoint inhibitors and other drugs and/or chemotherapy or radiotherapy, and effective models are now needed to select the best combinatorial regimen and disease setting.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Comment on

References

    1. Galluzzi L, Chan TA, Kroemer G, Wolchok JD, López-Soto A. The hallmarks of successful anticancer immunotherapy. Sci. Transl. Med. 2018;10:eaat7807. doi: 10.1126/scitranslmed.aat7807. - DOI - PubMed
    1. Wu FTH, Xu P, Chow A, Man S, Kruger J, Khan KA, et al. Pre-and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease. Br. J. Cancer. 2018 doi: 10.1038/s41416-018-0297-1. - DOI - PMC - PubMed
    1. Khan KA, Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat. Rev. Clin. Oncol. 2018;15:310–24. doi: 10.1038/nrclinonc.2018.9. - DOI - PubMed
    1. Samanta D, Park Y, Ni X, Li H, Zahnow CA, Gabrielson E, et al. Chemotherapy induces enrichment of CD47+/CD73+/PDL1+ immune evasive triple-negative breast cancer cells. Proc. Natl. Acad. Sci. USA. 2018;115:1239–48. doi: 10.1073/pnas.1718197115. - DOI - PMC - PubMed
    1. Orecchioni S, Talarico G, Labanca V, Calleri A, Mancuso P, Bertolini F. Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma. Br. J. Cancer. 2018;118:1329–36. doi: 10.1038/s41416-018-0076-z. - DOI - PMC - PubMed